<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00385268</url>
  </required_header>
  <id_info>
    <org_study_id>803895</org_study_id>
    <secondary_id>P60DA005186</secondary_id>
    <secondary_id>DPMC</secondary_id>
    <nct_id>NCT00385268</nct_id>
    <nct_alias>NCT00295451</nct_alias>
  </id_info>
  <brief_title>Pilot Trial of Acamprosate for the Treatment of Cocaine Dependence</brief_title>
  <acronym>CAMPRAL</acronym>
  <official_title>A Phase II, Double-Blind, Placebo-controlled, Pilot Trial of Acamprosate for the Treatment of Cocaine Dependence</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Pennsylvania</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Institute on Drug Abuse (NIDA)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>University of Pennsylvania</source>
  <oversight_info>
    <has_dmc>Yes</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Trial to determine the safety, efficacy and tolerability of acamprosate for the treatment of
      cocaine dependence.
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      The primary objective of the trial is to evaluate the safety, tolerability and efficacy of
      acamprosate for the treatment of 60 treatment seeking cocaine dependent outpatients. The
      study will be an exploratory, double-blind, placebo-controlled 9-week trial, with a 2-cell
      design (30 subjects per cell) in which either 1998 mg/day of acamprosate (666 mg TID) or
      placebo will be given. Study medications will be given by medical practitioners, trained to
      provide NIAAA's COMBINE Medical Management. In addition, patients will receive weekly
      individual psychosocial treatment sessions utilizing Cognitive Behavioral Therapy (CBT) at
      the University of Pennsylvania Treatment Research Center (TRC).

      Primary Hypotheses:

        1. Efficacy: Acamprosate-treated subjects will demonstrate less cocaine use during the
           medication/placebo treatment phase, compared to placebo-treated subjects. Cocaine use
           will be measured by self-report from the TLFB confirmed with urine assay for
           benzoylecgonine (BE)

        2. Safety and Tolerability: Acamprosate-treated subjects and placebo-treated subjects will
           report similar rates of adverse events, assessed by weekly evaluations, physical exams
           and laboratory testing.

      Secondary Hypotheses:

        1. Acamprosate-treated subjects, compared to placebo-treated subjects, will report less
           craving for cocaine, measured by lower scores on the Brief Substance Craving Scale
           (BSCS) (Somoza et al, 1995) and Multiple Choice Procedure (MCP) (Griffiths et al., 1993)
           during the medication treatment phase.

        2. Acamprosate-treated subjects, compared to placebo-treated subjects, will report fewer
           withdrawal symptoms, measured by the Cocaine Selective Severity Assessment (Kampman et
           al., 1998).

        3. Acamprosate-treated subjects, compared to placebo-treated subjects, will report fewer
           mood and anxiety symptoms, measured by the Hamilton Depression Rating Scale (HAM-D)
           (Hamilton, 1967), Hamilton Anxiety Rating Scale (HAM-A) (Hamilton, 1969), and Clinical
           Global Impression Scale (CGI).

        4. Subjects who are highly acamprosate-adherent (&gt;80% pills taken, verified by combining
           patient report with blister cards) will have more cocaine non-use days during the
           medication treatment phase, compared to those who are less acamprosate-adherent (&lt;80%
           pills taken).
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>November 2006</start_date>
  <completion_date type="Actual">July 2008</completion_date>
  <primary_completion_date type="Actual">May 2008</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>Quadruple (Participant, Care Provider, Investigator, Outcomes Assessor)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Cocaine Use Over the Eight Week Trial as Measured by Twice Weekly Urine Drug Screen</measure>
    <time_frame>8 weeks</time_frame>
    <description>cocaine abstinent weeks determined by all negative urine drug screens in each week (2 urine drug screens per week)</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">60</enrollment>
  <condition>Cocaine Dependence</condition>
  <arm_group>
    <arm_group_label>Active medication Acamprosate</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>1998mg/day for 8 weeks</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Placebo</arm_group_label>
    <arm_group_type>Placebo Comparator</arm_group_type>
    <description>placebo pills for 8 weeks</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>acamprosate</intervention_name>
    <description>1998 mg/dau fpr 8 weeks</description>
    <arm_group_label>Active medication Acamprosate</arm_group_label>
    <other_name>Campral</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>placebo</intervention_name>
    <description>placebo pills</description>
    <arm_group_label>Placebo</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria

          1. Male and females 18 years of age or older.

          2. Subject meets DSM-IV criteria for current diagnose of cocaine dependence, determined
             by The Structured Clinical Interview for DSM-IV (SCID-IV).

          3. Subject used cocaine in the past 30 days totaling at least $200 worth of cocaine.
             Cocaine use will be determined by utilizing the modified Timeline Followback,
             crosschecked with the ASI, which inquires about dollar amounts spent on drug use.

          4. Subject lives a commutable distance from the TRC and agrees to attend all research
             visits, including follow-up visits.

          5. Subject speaks, understands, and prints in English.

          6. Written informed consent signed by the subject.

        Exclusion Criteria

          1. Subjects mandated to treatment based upon a legal decision or as a condition of
             employment.

          2. Subjects with evidence of current substance dependence other than cocaine, alcohol or
             nicotine dependence, as determined by the SCID-IV.

          3. Subjects who meets DSM-IV criteria for current alcohol dependence who require a
             medical alcohol detoxification.

          4. Requires treatment with any psychoactive medications, including any anti-seizure
             medications (with the exception of Benadryl used sparingly, if necessary, for sleep).

          5. Has a lifetime DSM-IV diagnosis of bipolar affective disorder, schizophrenia or any
             psychotic disorder, or organic mental disorder. Has current DSM-IV diagnosis of any
             other clinically significant psychiatric disorder that will interfere with study
             participation, as determined by the study physician or PI (Drs. Kyle Kampman, Charles
             Dackis and Helen Pettinati).

          6. Female subjects who are pregnant or lactating, or female subjects of childbearing
             potential who are not using acceptable methods of birth control. Acceptable methods of
             birth control include: barrier (diaphragm or condom) with spermicide, intrauterine
             progesterone contraceptive system, levonorgestrel implant, medroxyprogesterone acetate
             contraceptive injection, and oral contraceptives.

          7. Clinical laboratory tests (CBC, blood chemistries, urinalysis) outside normal limits
             that are clinically unacceptable to the Principal Investigator. EKG-1st degree heart
             block, sinus tachycardia, left axis deviation, and nonspecific ST or T wave changes
             are allowed; liver function tests [LFTs] &lt; 5 x ULN are acceptable. Eligibility will be
             determined by most recent lab results collected prior to randomization.

          8. Subjects with impaired renal function as indicated by corrected creatinine clearance
             below 80 ml/min/70 kg as determined by the modified Cockcroft equation (Center for
             Disease Control, 1986).

          9. Subjects who have any disease of the gastrointestinal tract, liver or kidneys that
             could result in a possibility of altered metabolism or excretion of the study drug. As
             it is not possible to enumerate the many conditions which might impair absorption,
             metabolism, or excretion, the investigators will be guided by evidence such as:
             History of major gastrointestinal tract surgery (gastrectomy, gastrostomy, bowel
             resection, etc) or a history of an active peptic ulcer or chronic disease of the GI
             tract (ulcerative colitis, regional enteritis, or gastrointestinal bleeding).

         10. History of significant heart disease (an arrhythmia which required medication, angina
             pectoris, documented history of myocardial infarction, or heart failure).

         11. Known hypersensitivity to acamprosate.

         12. Subjects having participated in any investigational drug trial within 30 days prior to
             randomizing into the study.

         13. Subjects with any serious illnesses that may require hospitalization during the study,
             as determined by the study physician or PI (Drs. Kyle Kampman, Charles Dackis and
             Helen Pettinati).
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Helen Pettinati, Ph.D.</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Pennsylvania</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>University of Pennsylvania</name>
      <address>
        <city>Philadelphia</city>
        <state>Pennsylvania</state>
        <zip>19104</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>September 2018</verification_date>
  <study_first_submitted>October 6, 2006</study_first_submitted>
  <study_first_submitted_qc>October 6, 2006</study_first_submitted_qc>
  <study_first_posted type="Estimate">October 9, 2006</study_first_posted>
  <results_first_submitted>August 28, 2013</results_first_submitted>
  <results_first_submitted_qc>November 11, 2013</results_first_submitted_qc>
  <results_first_posted type="Estimate">December 31, 2013</results_first_posted>
  <last_update_submitted>June 24, 2020</last_update_submitted>
  <last_update_submitted_qc>June 24, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 10, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Pennsylvania</investigator_affiliation>
    <investigator_full_name>Kyle Kampman</investigator_full_name>
    <investigator_title>Principal Investigator</investigator_title>
  </responsible_party>
  <keyword>cocaine</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Cocaine-Related Disorders</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Acamprosate</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <group_list>
        <group group_id="P1">
          <title>Acamprosate</title>
          <description>1998mg/day for 8 weeks
Cognitive Behavioral Therapy : Weekly individual psychosocial treatment sessions.
acamprosate : 1998 mg/dau fpr 8 weeks</description>
        </group>
        <group group_id="P2">
          <title>Placebo</title>
          <description>placebo pills for 8 weeks
Cognitive Behavioral Therapy : Weekly individual psychosocial treatment sessions.
placebo : placebo pills</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="34"/>
                <participants group_id="P2" count="26"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="18"/>
                <participants group_id="P2" count="18"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="16"/>
                <participants group_id="P2" count="8"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Acamprosate</title>
          <description>1998mg/day for 8 weeks
Cognitive Behavioral Therapy : Weekly individual psychosocial treatment sessions.
acamprosate : 1998 mg/dau fpr 8 weeks</description>
        </group>
        <group group_id="B2">
          <title>Placebo</title>
          <description>placebo pills for 8 weeks
Cognitive Behavioral Therapy : Weekly individual psychosocial treatment sessions.
placebo : placebo pills</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="34"/>
            <count group_id="B2" value="26"/>
            <count group_id="B3" value="60"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Age</title>
          <units>years</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="45.3" spread="8.8"/>
                    <measurement group_id="B2" value="46.1" spread="7.7"/>
                    <measurement group_id="B3" value="45.5" spread="7.0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="15"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="25"/>
                    <measurement group_id="B2" value="20"/>
                    <measurement group_id="B3" value="45"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="34"/>
                    <measurement group_id="B2" value="26"/>
                    <measurement group_id="B3" value="60"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Cocaine Use Over the Eight Week Trial as Measured by Twice Weekly Urine Drug Screen</title>
        <description>cocaine abstinent weeks determined by all negative urine drug screens in each week (2 urine drug screens per week)</description>
        <time_frame>8 weeks</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Acamprosate</title>
            <description>1998mg/day for 8 weeks
Cognitive Behavioral Therapy : Weekly individual psychosocial treatment sessions.
acamprosate : 1998 mg/dau fpr 8 weeks</description>
          </group>
          <group group_id="O2">
            <title>Placebo</title>
            <description>placebo pills for 8 weeks
Cognitive Behavioral Therapy : Weekly individual psychosocial treatment sessions.
placebo : placebo pills</description>
          </group>
        </group_list>
        <measure>
          <title>Cocaine Use Over the Eight Week Trial as Measured by Twice Weekly Urine Drug Screen</title>
          <description>cocaine abstinent weeks determined by all negative urine drug screens in each week (2 urine drug screens per week)</description>
          <units>cocaine abstinent weeks</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="34"/>
                <count group_id="O2" value="26"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="1.3" spread="2.3"/>
                    <measurement group_id="O2" value="1.2" spread="2.3"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <analysis_list>
          <analysis>
            <group_id_list>
              <group_id>O1</group_id>
              <group_id>O2</group_id>
            </group_id_list>
            <non_inferiority_type>Superiority</non_inferiority_type>
            <p_value>0.44</p_value>
            <method>GEE model of repeated measures</method>
            <method_desc>GEE on repeated binary indicators of BE positive / negative test</method_desc>
            <param_type>Odds Ratio (OR)</param_type>
            <param_value>1.68</param_value>
            <ci_percent>95</ci_percent>
            <ci_n_sides>2-Sided</ci_n_sides>
            <ci_lower_limit>0.55</ci_lower_limit>
            <ci_upper_limit>5.14</ci_upper_limit>
          </analysis>
        </analysis_list>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Acamprosate</title>
          <description>1998mg/day for 8 weeks
Cognitive Behavioral Therapy : Weekly individual psychosocial treatment sessions.
acamprosate : 1998 mg/dau fpr 8 weeks</description>
        </group>
        <group group_id="E2">
          <title>Placebo</title>
          <description>placebo pills for 8 weeks
Cognitive Behavioral Therapy : Weekly individual psychosocial treatment sessions.
placebo : placebo pills</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>5</frequency_threshold>
        <default_assessment>Non-systematic Assessment</default_assessment>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
          <category>
            <title>General disorders</title>
            <event_list>
              <event>
                <sub_title>Aches and Pains</sub_title>
                <counts group_id="E1" subjects_affected="13" subjects_at_risk="34"/>
                <counts group_id="E2" subjects_affected="13" subjects_at_risk="26"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>Dr. Helen Pettinati</name_or_title>
      <organization>University of Pennsylvania</organization>
      <phone>215-222-3200 ext 139</phone>
      <email>helenp@mail.med.upenn.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

